351 related articles for article (PubMed ID: 19487281)
1. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
2. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
O'Kane SL; Cawkwell L; Campbell A; Lind MJ
Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
Bahnassy AA; Zekri AR; Abou-Bakr AA; El-Deftar MM; El-Bastawisy A; Sakr MA; El-Sherif GM; Gaafar RM
Exp Mol Pathol; 2012 Aug; 93(1):154-61. PubMed ID: 22504106
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor subtypes in ovarian cancer: a clinical correlation.
Chan KK; Wei N; Liu SS; Xiao-Yun L; Cheung AN; Ngan HY
Obstet Gynecol; 2008 Jan; 111(1):144-51. PubMed ID: 18165403
[TBL] [Abstract][Full Text] [Related]
10. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
Jennings CJ; O'Grady A; Cummins R; Murer B; Al-Alawi M; Madden SF; Mutti L; Harvey BJ; Thomas W; Kay EW
J Thorac Oncol; 2012 Jan; 7(1):243-8. PubMed ID: 22011668
[TBL] [Abstract][Full Text] [Related]
11. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
Mineo TC; Ambrogi V; Cufari ME; Pompeo E
Eur J Cardiothorac Surg; 2010 Sep; 38(3):245-52. PubMed ID: 20338775
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
[TBL] [Abstract][Full Text] [Related]
13. Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer.
Sumi K; Matsuyama S; Kitajima Y; Miyazaki K
Oncol Rep; 2004 Nov; 12(5):979-84. PubMed ID: 15492781
[TBL] [Abstract][Full Text] [Related]
14. Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients.
Jubelirer SJ; Garcelon J
W V Med J; 1997; 93(3):120-5. PubMed ID: 9197186
[TBL] [Abstract][Full Text] [Related]
15. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
16. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.
Kao SC; Armstrong N; Condon B; Griggs K; McCaughan B; Maltby S; Wilson A; Henderson DW; Klebe S
Cancer; 2012 Jun; 118(11):2952-61. PubMed ID: 22020536
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
[TBL] [Abstract][Full Text] [Related]
19. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
Piffer S; Zeni G; Aldovini D; Polla E; Peterlongo P
Minerva Med; 1989 Apr; 80(4):405-10. PubMed ID: 2725943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
